Brett Winborn, Ph.D.


Contact info


Contact info


Dr. Winborn focuses his practice on helping innovators within the biotechnology, life science, and medical device fields craft comprehensive protection strategies for their technologies. He partners with clients through all stages of the patent development process from due diligence and freedom-to-operate intelligence to prosecution and post-grant proceedings. Dr. Winborn’s practice focuses on molecular and cellular biology including the areas of biochemistry, microbiology, nutraceuticals, therapeutic methods, and genetic engineering.

Dr. Winborn previously worked as a research assistant and legal extern with the University of Iowa where he drafted provisional patent applications, office action responses, prior art searches, and claim charts. Dr. Winborn holds a bachelor of science degree from the University of Miami, as well as a doctoral degree and a law degree from the University of Iowa. While in law school, he received the Innovation, Business, and Law Excellence Award from the College of Law.

Before pursuing a legal career, Dr. Winborn served as a postdoctoral research fellow at St. Jude Children’s Research Hospital where he developed an innovative proteomics-based approach to network biology to successfully predict new disease genes. His work resulted in the identification of a new causative gene for ALS. He also regularly collaborated with scientists on a range of research and development projects involving disease genetics and biology. His technical experience includes work on proteomics, genomics, transcriptomics, bioinformatics, genetics, antibody development, RNA interference, and protein and nucleic acid technologies.

University of Iowa College of Law (JD, 2019)
University of Iowa (Ph.D. in Molecular and Cellular Biology, 2008)
University of Miami (BS, 2002)

  • Patent Office Post Grant Proceedings
  • Patent Prosecution
  • Patent Search Services
  • Green Technology
  • Life Sciences
  • Pharmaceuticals

Iowa (inactive)


Patent Owners Versus the Supreme Court: Changing the Law Underlying Patent Eligible Subject Matter, Journal of Corporation Law

Badders NM, Korff, A, Miranda HC, Vuppala PK, Smith, RB, Winborn BJ, Quemin ER, Sopher BL, Dearman J, Messing J, Kim NC, Moore J, Freibaum BD, Kanagaraj AP, Fan B, Tillman H, Chen PC, Wang Y, Freeman BB, Li Y, Kim HJ, La Spada AR, Taylor JP. Selective Modulation of the Androgen receptor AF2 domain rescues degeneration in spinal bulbar muscular atrophy. Nature Medicine. 2018 May;24(4):427-37.

Johnson JO, Pioro EP, Boehringer A, Chia R, Feit H, Renton AE, Pliner HA, Abramzon Y, Marangi G, Winborn BJ, Gibbs JR, Nalls MA, Morgan S, Shoai M, Hardy J, Pittman A, Orrell RW, Malaspina A, Sidle KC, Fratta P, Harms MB, Baloh RH, Pestronk A, Weihl CC, Rogaeva E, Zinman L, Drory VE, Borghero G, Mora G, Calvo A, Rothstein JD; ITALSGEN, Drepper C, Sendtner M, Singleton AB, Taylor JP, Cookson MR, Restagno G, Sabatelli M, Bowser R, Chiò A, Traynor BJ. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nature Neuroscience. 2014 May;17(5):664-6.

Alami NH, Smith RB, Carrasco MA, Williams LA, Winborn CS, Han SS, Kiskinis E, Winborn BJ, Freibaum BD, Kanagaraj A, Clare AJ, Badders NM, Bilican B, Chaum E, Chandran S, Shaw CE, Eggan KC, Maniatis T, Taylor JP. Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron. 2014 Feb 5;81(3):536-43.

Kim NC, Tresse E, Kolaitis RM, Molliex A, Thomas RE, Alami NH, Wang B, Joshi A, Smith RB, Ritson GP, Winborn BJ, Moore J, Lee JY, Yao TP, Palanck L, Kundu M and Taylor JP. VCP is essential for mitochondrial quality control by PINK1/Parkin and this function is impaired by VCP mutations. Neuron. 2013 Apr 10; 78 (1):65-80.

Todi SV, Winborn BJ, Scaglione KM, Blount JR, Travis SM, Paulson HL. Ubiquitination directly enhances activity of the deubiquitinating enzyme ataxin-3. EMBO Journal. 2009 Feb 18; 28 (4):372-82.

Winborn BJ, Travis SM, Todi SV, Scaglione KM, Xu P, Williams AJ, Cohen RE, Peng J, Paulson HL. The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits K63-linkages in mixed linkage ubiquitin chains. Journal of Biological Chemistry, 2008 Sep 26; 283 (39):26436-43.